ICER publishes final evidence report on lecanemab for Alzheimer’s disease

ICER

17 April 2023 - Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if priced between $8,900 – $21,500/year.

The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of lecanemab for the treatment of Alzheimer’s disease.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder